Guardant Health, Inc. (GH) Q3 2026 earnings results
Guardant Health, Inc. (GH) reported Q3 2026 results on Nov 5, 2026, 4:08:46 PM ET: adjusted EPS -$0.29 vs. -$0.31 expected (beat by 7.8%); revenue $360.98M vs. $350.64M expected (beat by 2.9%). Outlook: Full year 2026 revenue guidance raised to $1.36 to $1.37 billion.
| Metric | Reported | Analyst estimate | Result |
|---|---|---|---|
| EPS (adjusted, diluted) | -$0.29 | -$0.31 | Beat by 7.8% |
| Revenue | $360.98M | $350.64M | Beat by 2.9% |
Analyst estimate: the average forecast before the release.
Source
Figures from the SEC 8-K filing, released Nov 5, 2026, 4:08:46 PM ET. Nexqual published them 63 seconds after release. Each figure is confirmed by two independent extraction methods before it is published.
Year over year
Compared with the same quarter a year earlier (ended September 30, 2025, from the company's SEC filing): revenue grew 36.1% from $265.20M.
Stock reaction
The results came out after the market closed. GH closed at $150.87 on November 6, 2026, down 1.7% from its $153.43 close on November 5, 2026 before the results. Latest: $157.13 as of 11:40 AM ET, +2.4% since the pre-release close.
Questions and answers
Did Guardant Health, Inc. beat earnings expectations?
Yes. Guardant Health, Inc. reported adjusted EPS of -$0.29 against an average analyst estimate of -$0.31 (beat by 7.8%), and revenue of $360.98M against $350.64M expected (beat by 2.9%).
What were Guardant Health, Inc.'s Q3 2026 earnings and revenue?
adjusted diluted EPS of -$0.29 and revenue of $360.98M. Compared with the same quarter a year earlier (ended September 30, 2025, from the company's SEC filing): revenue grew 36.1% from $265.20M.
When did Guardant Health, Inc. report Q3 2026 earnings?
Nov 5, 2026, 4:08:46 PM ET, in an SEC 8-K filing (Item 2.02).
How did GH stock react to the earnings?
The results came out after the market closed. GH closed at $150.87 on November 6, 2026, down 1.7% from its $153.43 close on November 5, 2026 before the results. Latest: $157.13 as of 11:40 AM ET, +2.4% since the pre-release close.
What did Guardant Health, Inc. say about its outlook?
Full year 2026 revenue guidance raised to $1.36 to $1.37 billion.
More on GH
GH stock page: price, SEC financials, insider trades, superinvestor holders, analyst estimates and options. All results reported that day: earnings November 5, 2026.
Source: SEC EDGAR 8-K (Item 2.02), Nexqual Earnings Flash. Built November 10, 2026 at 16:40 UTC. Not investment advice.
Data source: Nexqual. Last updated: November 10, 2026 at 16:40 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt